<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24478435</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Surfactant-modified nanoclay exhibits an antiviral activity with high potency and broad spectrum.</ArticleTitle><Pagination><StartPage>4218</StartPage><EndPage>4228</EndPage><MedlinePgn>4218-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.03256-13</ELocationID><Abstract><AbstractText Label="UNLABELLED">Nanomaterials have the characteristics associated with high surface-to-volume ratios and have been explored for their antiviral activity. Despite some success, cytotoxicity has been an issue in nanomaterial-based antiviral strategies. We previously developed a novel method to fully exfoliate montmorillonite clay to generate the most fundamental units of nanoscale silicate platelet (NSP). We further modified NSP by capping with various surfactants and found that the surfactant-modified NSP (NSQ) was less cytotoxic. In this study, we tested the antiviral potentials of a series of natural-clay-derived nanomaterials. Among the derivatives, NSP modified with anionic sodium dodecyl sulfate (NSQc), but not the pristine clay, unmodified NSP, a silver nanoparticle-NSP hybrid, NSP modified with cationic n-octadecanylamine hydrochloride salt, or NSP modified with nonionic Triton X-100, significantly suppressed the plaque-forming ability of Japanese encephalitis virus (JEV) at noncytotoxic concentrations. NSQc also blocked infection with dengue virus (DEN) and influenza A virus. Regarding the antiviral mechanism, NSQc interfered with viral binding through electrostatic interaction, since its antiviral activity can be neutralized by Polybrene, a cationic polymer. Furthermore, NSQc reduced the lethality of JEV and DEN infection in mouse challenge models. Thus, the surfactant-modified exfoliated nanoclay NSQc may be a novel nanomaterial with broad and potent antiviral activity.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Nanomaterials have being investigated as antimicrobial agents, yet their antiviral potential is overshadowed by their cytotoxicity. By using a novel method, we fully exfoliated montmorillonite clay to generate the most fundamental units of nanoscale silicate platelet (NSP). Here, we show that the surfactant-modified NSP (NSQ) is less cytotoxic and that NSQc (NSP modified with sodium dodecyl sulfate) could potently block infection by dengue virus (DEN), Japanese encephalitis virus (JEV), and influenza A virus at noncytotoxic concentrations. For the antiviral mechanism, we find that the electrostatic interaction between the negatively charged NSQc and the positively charged virus particles blocks viral binding. Furthermore, we used mouse challenge models of JEV and DEN to demonstrate the in vivo antiviral potential of NSQc. Thus, NSQc may function as a potent and safe antiviral nanohybrid against several viruses, and our success in synthesizing surfactant-modified NSP with antiviral activity may shed some light on future antiviral development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jian-Jong</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jiun-Chiou</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yi-Ling</ForeName><Initials>YL</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Shan-hui</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jiang-Jen</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Ling</ForeName><Initials>YL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013501">Surface-Active Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1302-78-9</RegistryNumber><NameOfSubstance UI="D001546">Bentonite</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-93-1</RegistryNumber><NameOfSubstance UI="D017830">Octoxynol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001546" MajorTopicYN="N">Bentonite</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004664" MajorTopicYN="N">Encephalitis Virus, Japanese</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004672" MajorTopicYN="N">Encephalitis, Japanese</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017830" MajorTopicYN="N">Octoxynol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013501" MajorTopicYN="N">Surface-Active Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24478435</ArticleId><ArticleId IdType="pmc">PMC3993779</ArticleId><ArticleId IdType="doi">10.1128/JVI.03256-13</ArticleId><ArticleId IdType="pii">JVI.03256-13</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, Xiang N, Chen E, Tang F, Wang D, Meng L, Hong Z, Tu W, Cao Y, Li L, Ding F, Liu B, Wang M, Xie R, Gao R, Li X, Bai T, Zou S, He J, Hu J, Xu Y, Chai C, Wang S, Gao Y, Jin L, Zhang Y, Luo H, Yu H, Gao L, Pang X, Liu G, Shu Y, Yang W, Uyeki TM, Wang Y, Wu F, Feng Z. 24 April 2013. Preliminary report: epidemiology of the avian influenza A (H7N9) outbreak in China. N. Engl. J. Med. 10.1056/NEJMoa1304617</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304617</ArticleId><ArticleId IdType="pmc">PMC6652192</ArticleId><ArticleId IdType="pubmed">23614499</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons CP, Farrar JJ, Nguyen VV, Wills B. 2012. Dengue. N. Engl. J. Med. 366:1423&#x2013;1432. 10.1056/NEJMra1110265</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1110265</ArticleId><ArticleId IdType="pubmed">22494122</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW. 2010. Dengue: a continuing global threat. Nat. Rev. Microbiol. 8:S7&#x2013;16. 10.1038/nrmicro2460</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2460</ArticleId><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T. 2004. Flavivirus encephalitis. N. Engl. J. Med. 351:370&#x2013;378. 10.1056/NEJMra030476</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra030476</ArticleId><ArticleId IdType="pubmed">15269317</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz FX, Stiasny K. 2012. Flaviviruses and flavivirus vaccines. Vaccine 30:4301&#x2013;4306. 10.1016/j.vaccine.2011.09.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.09.114</ArticleId><ArticleId IdType="pubmed">22682286</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayce AC, Miller JL, Zitzmann N. 2010. Targeting a host process as an antiviral approach against dengue virus. Trends Microbiol. 18:323&#x2013;330. 10.1016/j.tim.2010.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2010.04.003</ArticleId><ArticleId IdType="pubmed">20452219</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera Gil P, Huhn D, del Mercato LL, Sasse D, Parak WJ. 2010. Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol. Res. 62:115&#x2013;125. 10.1016/j.phrs.2010.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2010.01.009</ArticleId><ArticleId IdType="pubmed">20097288</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain KK. 2008. Nanomedicine: application of nanobiotechnology in medical practice. Med. Princ. Pract. 17:89&#x2013;101. 10.1159/000112961</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000112961</ArticleId><ArticleId IdType="pubmed">18287791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. 2008. Emerging nanopharmaceuticals. Nanomedicine 4:273&#x2013;282. 10.1016/j.nano.2008.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2008.06.002</ArticleId><ArticleId IdType="pubmed">18640076</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M. 2011. Silver nanoparticles as potential antiviral agents. Molecules 16:8894&#x2013;8918. 10.3390/molecules16108894</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules16108894</ArticleId><ArticleId IdType="pmc">PMC6264685</ArticleId><ArticleId IdType="pubmed">22024958</ArticleId></ArticleIdList></Reference><Reference><Citation>Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. 2005. Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnol. 3:6. 10.1186/1477-3155-3-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-3155-3-6</ArticleId><ArticleId IdType="pmc">PMC1190212</ArticleId><ArticleId IdType="pubmed">15987516</ArticleId></ArticleIdList></Reference><Reference><Citation>Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R. 2009. Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug. Chem. 20:1497&#x2013;1502. 10.1021/bc900215b</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bc900215b</ArticleId><ArticleId IdType="pubmed">21141805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Sun RW, Chen R, Hui CK, Ho CM, Luk JM, Lau GK, Che CM. 2008. Silver nanoparticles inhibit hepatitis B virus replication. Antivir. Ther. 13:253&#x2013;262</Citation><ArticleIdList><ArticleId IdType="pubmed">18505176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Singh AK, Vig K, Pillai SR, Singh SR. 2008. Silver nanoparticles inhibit replication of respiratory syncytial virus. J. Biomed. Nanotechnol. 4:149&#x2013;158. 10.1166/jbn.2008.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jbn.2008.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang DX, Chen Q, Pang L, Zheng CL. 2011. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J. Virol. Methods 178:137&#x2013;142. 10.1016/j.jviromet.2011.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.09.003</ArticleId><ArticleId IdType="pubmed">21945220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae E, Park H, Park J, Yoon J, Kim Y, Choi K, Yi J. 2011. Effect of chemical stabilizers in silver nanoparticle suspensions on nanotoxicity. Bull. Korean Chem. Soc. 32:613&#x2013;619. 10.5012/bkcs.2011.32.2.613</Citation><ArticleIdList><ArticleId IdType="doi">10.5012/bkcs.2011.32.2.613</ArticleId></ArticleIdList></Reference><Reference><Citation>Maga&#xf1;a SM, Quintana P, Aguilar DH, Toledo JA, Angeles-Ch&#xe1;vez C, Cort&#xe9;s MA, Le&#xf3;n L, Freile-Pelegr&#xed;n Y, L&#xf3;pez T, S&#xe1;nchez RMT. 2008. Antibacterial activity of montmorillonites modified with silver. J. Mol. Catal. A: Chem. 281:192&#x2013;199. 10.1016/j.molcata.2007.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcata.2007.10.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams LB, Metge DW, Eberl DD, Harvey RW, Turner AG, Prapaipong P, Poret-Peterson AT. 2011. What makes a natural clay antibacterial? Environ. Sci. Technol. 45:3768&#x2013;3773. 10.1021/es1040688</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/es1040688</ArticleId><ArticleId IdType="pmc">PMC3126108</ArticleId><ArticleId IdType="pubmed">21413758</ArticleId></ArticleIdList></Reference><Reference><Citation>Haydel SE, Remenih CM, Williams LB. 2008. Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens. J. Antimicrob. Chemother. 61:353&#x2013;361. 10.1093/jac/dkm468</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkm468</ArticleId><ArticleId IdType="pmc">PMC2413170</ArticleId><ArticleId IdType="pubmed">18070832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinnavaia TJ. 1983. Intercalated clay catalysts. Science 220:365&#x2013;371. 10.1126/science.220.4595.365</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.220.4595.365</ArticleId><ArticleId IdType="pubmed">17831398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JJ, Chu CC, Chiang ML, Tsai WC. 2006. First isolation of individual silicate platelets from clay exfoliation and their unique self-assembly into fibrous arrays. J. Phys. Chem. B 110:18115&#x2013;18120. 10.1021/jp0636773</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jp0636773</ArticleId><ArticleId IdType="pubmed">16970422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu SH, Tseng HJ, Hung HS, Wang MC, Hung CH, Li PR, Lin JJ. 2009. Antimicrobial activities and cellular responses to natural silicate clays and derivatives modified by cationic alkylamine salts. ACS Appl. Mater. Interfaces 1:2556&#x2013;2564. 10.1021/am900479q</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/am900479q</ArticleId><ArticleId IdType="pubmed">20356127</ArticleId></ArticleIdList></Reference><Reference><Citation>Su HL, Chou CC, Hung DJ, Lin SH, Pao IC, Lin JH, Huang FL, Dong RX, Lin JJ. 2009. The disruption of bacterial membrane integrity through ROS generation induced by nanohybrids of silver and clay. Biomaterials 30:5979&#x2013;5987. 10.1016/j.biomaterials.2009.07.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2009.07.030</ArticleId><ArticleId IdType="pubmed">19656561</ArticleId></ArticleIdList></Reference><Reference><Citation>Su HL, Lin SH, Wei JC, Pao IC, Chiao SH, Huang CC, Lin SZ, Lin JJ. 2011. Novel nanohybrids of silver particles on clay platelets for inhibiting silver-resistant bacteria. PLoS One 6:e21125. 10.1371/journal.pone.0021125</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021125</ArticleId><ArticleId IdType="pmc">PMC3117870</ArticleId><ArticleId IdType="pubmed">21695045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiao SH, Lin SH, Shen CI, Liao JW, Bau IJ, Wei JC, Tseng LP, Hsu SH, Lai PS, Lin SZ, Lin JJ, Su HL. 2012. Efficacy and safety of nanohybrids comprising silver nanoparticles and silicate clay for controlling Salmonella infection. Int. J. Nanomed. 7:2421&#x2013;2432. 10.2147/IJN.S31594</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S31594</ArticleId><ArticleId IdType="pmc">PMC3363949</ArticleId><ArticleId IdType="pubmed">22654516</ArticleId></ArticleIdList></Reference><Reference><Citation>Teow Y, Asharani PV, Hande MP, Valiyaveettil S. 2011. Health impact and safety of engineered nanomaterials. Chem. Commun. (Camb.) 47:7025&#x2013;7038. 10.1039/c0cc05271j</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c0cc05271j</ArticleId><ArticleId IdType="pubmed">21479319</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MC, Lin JJ, Tseng HJ, Hsu SH. 2012. Characterization, antimicrobial activities, and biocompatibility of organically modified clays and their nanocomposites with polyurethane. ACS Appl. Mater. Interfaces 4:338&#x2013;350. 10.1021/am2014103</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/am2014103</ArticleId><ArticleId IdType="pubmed">22128903</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang JJ, Liao CL, Liao JT, Lee YL, Lin YL. 2009. A Japanese encephalitis virus vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability. Vaccine 27:2746&#x2013;2754. 10.1016/j.vaccine.2009.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.007</ArticleId><ArticleId IdType="pubmed">19366580</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, Huang YY, Huang YL, Kao CL, King CC. 1998. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72:9729&#x2013;9737</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110483</ArticleId><ArticleId IdType="pubmed">9811707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LK, Liao CL, Lin CG, Lai SC, Liu CI, Ma SH, Huang YY, Lin YL. 1996. Persistence of Japanese encephalitis virus is associated with abnormal expression of the nonstructural protein NS1 in host cells. Virology 217:220&#x2013;229. 10.1006/viro.1996.0109</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1996.0109</ArticleId><ArticleId IdType="pubmed">8599206</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang JJ, Yu CY, Liao CL, Lin YL. 2011. Vimentin binding is critical for infection by the virulent strain of Japanese encephalitis virus. Cell. Microbiol. 13:1358&#x2013;1370. 10.1111/j.1462-5822.2011.01624.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2011.01624.x</ArticleId><ArticleId IdType="pubmed">21707907</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin JE, Hackenmiller R, Simon MC, Levy DE. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443&#x2013;450. 10.1016/S0092-8674(00)81289-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81289-1</ArticleId><ArticleId IdType="pubmed">8608598</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LK, Lin YL, Liao CL, Lin CG, Huang YL, Yeh CT, Lai SC, Jan JT, Chin C. 1996. Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology 223:79&#x2013;88. 10.1006/viro.1996.0457</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1996.0457</ArticleId><ArticleId IdType="pubmed">8806542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hase T, Dubois DR, Summers PL. 1990. Comparative study of mouse brains infected with Japanese encephalitis virus by intracerebral or intraperitoneal inoculation. Int. J. Exp. Pathol. 71:857&#x2013;869</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2002376</ArticleId><ArticleId IdType="pubmed">2177623</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu YC, Yu CY, Liang JJ, Lin E, Liao CL, Lin YL. 2012. Blocking double-stranded RNA-activated protein kinase PKR by Japanese encephalitis virus nonstructural protein 2A. J. Virol. 86:10347&#x2013;10358. 10.1128/JVI.00525-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00525-12</ArticleId><ArticleId IdType="pmc">PMC3457255</ArticleId><ArticleId IdType="pubmed">22787234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Sasaki M, Okumura M, Kim E, Sawa H. 2010. Flavivirus encephalitis: pathological aspects of mouse and other animal models. Vet. Pathol. 47:806&#x2013;818. 10.1177/0300985810372507</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300985810372507</ArticleId><ArticleId IdType="pubmed">20551474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, Lin YL. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76:3596&#x2013;3604. 10.1128/JVI.76.8.3596-3604.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.8.3596-3604.2002</ArticleId><ArticleId IdType="pmc">PMC136089</ArticleId><ArticleId IdType="pubmed">11907199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Shresta S. 2008. Mouse models of dengue virus infection and disease. Antiviral Res. 80:87&#x2013;93. 10.1016/j.antiviral.2008.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.06.010</ArticleId><ArticleId IdType="pmc">PMC3048811</ArticleId><ArticleId IdType="pubmed">18619493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL. 2008. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453:672&#x2013;676. 10.1038/nature07013</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07013</ArticleId><ArticleId IdType="pubmed">18496526</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HJ, Lin JJ, Ho TT, Tseng SM, Hsu SH. 2011. The biocompatibility and antimicrobial activity of nanocomposites from polyurethane and nano silicate platelets. J. Biomed. Mater. Res. A 99:192&#x2013;202. 10.1002/jbm.a.33175</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.33175</ArticleId><ArticleId IdType="pubmed">21976444</ArticleId></ArticleIdList></Reference><Reference><Citation>Piret J, Desormeaux A, Bergeron MG. 2002. Sodium lauryl sulfate, a microbicide effective against enveloped and nonenveloped viruses. Curr. Drug Targets 3:17&#x2013;30. 10.2174/1389450023348037</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450023348037</ArticleId><ArticleId IdType="pubmed">11899262</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker H, Ryan M, Jaenicke E, Terwilliger N. 2001. SDS-induced phenoloxidase activity of hemocyanins from Limulus polyphemus, Eurypelma californicum, and Cancer magister. J. Biol. Chem. 276:17796&#x2013;17799. 10.1074/jbc.M010436200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M010436200</ArticleId><ArticleId IdType="pubmed">11278677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstern P, Solheim BG. 2011. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus. Med. Hemother. 38:65&#x2013;70. 10.1159/000323552</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000323552</ArticleId><ArticleId IdType="pmc">PMC3132981</ArticleId><ArticleId IdType="pubmed">21779207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Lei HY, Wen YY, Luh TY, Chou CK, Liu HS. 2000. Light-independent inactivation of dengue-2 virus by carboxyfullerene C3 isomer. Virology 275:258&#x2013;262. 10.1006/viro.2000.0490</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0490</ArticleId><ArticleId IdType="pubmed">10998325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenbach BD, Thiel H-J, Rice CM. 2007. Flaviviridae: the viruses and their replication, p 1101&#x2013;1152 In Knipe DM, Howley PM. (ed), Fields virology, 5th ed, vol 1 Lippincott Williams &amp; Wilkins, Philadelphia, PA</Citation></Reference><Reference><Citation>Su CM, Liao CL, Lee YL, Lin YL. 2001. Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection. Virology 286:206&#x2013;215. 10.1006/viro.2001.0986</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2001.0986</ArticleId><ArticleId IdType="pubmed">11448173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866&#x2013;871. 10.1038/nm0897-866</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0897-866</ArticleId><ArticleId IdType="pubmed">9256277</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M. 2012. Influenza virus entry. Adv. Exp. Med. Biol. 726:201&#x2013;221. 10.1007/978-1-4614-0980-9_9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-0980-9_9</ArticleId><ArticleId IdType="pmc">PMC7123407</ArticleId><ArticleId IdType="pubmed">22297515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS. 2008. Evolving complexities of influenza virus and its receptors. Trends Microbiol. 16:149&#x2013;157. 10.1016/j.tim.2008.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2008.01.008</ArticleId><ArticleId IdType="pubmed">18375125</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh MG. 2012. The role of hydrogeography and climate in the landscape epidemiology of West Nile virus in New York State from 2000 to 2010. PLoS One 7:e30620. 10.1371/journal.pone.0030620</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030620</ArticleId><ArticleId IdType="pmc">PMC3273478</ArticleId><ArticleId IdType="pubmed">22328919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M. 2012. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12:240&#x2013;248. 10.1016/S1473-3099(11)70318-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(11)70318-8</ArticleId><ArticleId IdType="pubmed">22186145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>